scholarly journals Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis

2021 ◽  
Vol 9 (5) ◽  
Author(s):  
Elodie Charuel ◽  
Thibault Menini ◽  
Sabrina Bedhomme ◽  
Bruno Pereira ◽  
Nathalie Piñol‐Domenech ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Chronic Heart Failure ◽  
Adverse Effects ◽  
Meta Analysis

scholarly journals Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-18
Author(s):  
Xiaoming Xu ◽  
Yang Yang ◽  
Gendong Zhou ◽  
Zhengxuan Du ◽  
Xiaohong Zhang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Chronic Heart Failure ◽  
Adverse Effects ◽  
Clinical Efficacy ◽  
Western Medicine ◽  
Methodological Quality ◽  
Meta Analysis ◽  
Large Sample Size

Qili Qiangxin capsule (QQC) is a formulation of traditional Chinese medicine commonly used for the treatment of heart failure in China. This meta-analysis aimed to assess the clinical efficacy of QQC combined with western medicine in the treatment of chronic heart failure (CHF). We conducted a systematic review and meta-analysis abided by the PRISMA guidelines. Literature search was conducted in the China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journals Database, PubMed, and Web of Science from inception to August 2020. A total of 52 eligible studies were obtained, and 42 of these studies were included in the meta-analysis. The results showed that, compared with western medicine alone, the combination of Qili Qingxin capsule and Western medicine treatment has better efficacy (metoprolol: RR: 1.24, 95%CI 1.14–1.34; carvedilol: RR: 1.24, 95%CI 1.14–1.34; trimetazidine: RR: 1.20, 95%CI: 1.12–1.27; sacubitril valsartan sodium: RR: 1.23, 95%CI: 1.11–1.36; sodium nitroprusside: RR: 1.33, 95%CI: 1.23–1.45; and bisoprolol: RR: 1.31, 95%CI: 1.15–1.49) and increased the level of LVEF, LVEDD, and 6MWT of patients with CHF and reduced the adverse effects and the level of HR, LVESD, BNP, and Hs-cTnT as well. However, there is high heterogeneity in the meta-analysis of LVEDV, BNP, NT-proBNP, Hs-cTnT, 6MWT, and adverse effects, and the methodological quality of the included studies was poor. Therefore, further studies with good methodological quality and large sample size are required to validate our findings. In our study, evidence suggests that Qili Qiangxin capsule combined with Western medicine may improve therapeutic effect and the quality of life of patients with CHF.

Quality of life of chronic heart failure patients: a systematic review and meta-analysis

2019 ◽  
Vol 25 (6) ◽  
pp. 993-1006 ◽  
Author(s):  
Mandana Moradi ◽  
Fereshteh Daneshi ◽  
Razieh Behzadmehr ◽  
Hosien Rafiemanesh ◽  
Salehoddin Bouya ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Systematic Review ◽  
Chronic Heart Failure ◽  
Meta Analysis ◽  
Heart Failure Patients

Effects of traditional Chinese exercise in patients with chronic heart failure: A systematic review and meta-analysis

2020 ◽  
Vol 40 ◽  
pp. 101218
Author(s):  
Yuan Liao ◽  
Hao Wen ◽  
Shuqi Ge ◽  
Wanhua Zhong ◽  
Yanchang Liang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Chronic Heart Failure ◽  
Meta Analysis

Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis

2014 ◽  
Vol 20 (7) ◽  
pp. 522-532 ◽  
Author(s):  
Ingrid Hopper ◽  
Rohit Samuel ◽  
Christopher Hayward ◽  
Andrew Tonkin ◽  
Henry Krum
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Chronic Heart Failure ◽  
Meta Analysis

scholarly journals Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 24 (2) ◽  
pp. E327-E332
Author(s):  
Chenxia Wu ◽  
Zhengtian Lv ◽  
Xinyi Li ◽  
Xinbing Zhou ◽  
Wei Mao ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Chronic Heart Failure ◽  
Cardiac Fibrosis ◽  
Inflammatory Marker ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Heart Failure Patients ◽  
Galectin 3 ◽  
The Cochrane Library

Background: In recent years, galectin-3, an inflammatory marker, has been demonstrated to be closely related to cardiac fibrosis and heart failure. The purpose of this systematic review and meta-analysis is to define galectin-3 in predicting mortality of heart failure. Methods: PubMed, Embase, and the Cochrane Library were searched. A total of 1540 studies were identified, and of these studies, 19 involving 9217 patients were included in our meta-analysis. Results: The diagnostic hazard ratios of galectin-3 in predicting mortality in chronic heart failure patients was 1.13 (95% CI,:1.07-1.21 ) and 2.17 (95% CI:1.27-3.08) in acute heart failure (HF) patients. Conclusions: Our meta-analysis shows that elevated levels of galectin-3 are associated with higher mortality in both acute and chronic heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document